Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Non-comparative, Multi-center, Post-market Clinical Study to Evaluate the Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages for the Treatment of Degenerative Disc Disease and Spondylolisthesis in the Lumbar Spine

NCT03928041 is registered in ClinicalTrials.gov with Invibio Ltd as lead sponsor.

NCT NCT03928041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03928041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Non-comparative, Multi-center, Post-market Clinical Study to Evaluate the Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages for the Treatment of Degenerative Disc Disease and Spondylolisthesis in the Lumbar Spine
Lead sponsor
Invibio Ltd
Phase
Not applicable
Overall status
Completed
Start date
June 27, 2019
Completion date
September 25, 2023
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative disc disease lumbar, spondylolisthesis, grade 1